Current role of systematic biopsy in diagnosis of clinically significant prostate cancer in primary combined MRI-targeted biopsy: a high-volume single-center study

1

The study analyzed the role of systematic biopsy (SB) in detecting clinically significant prostate cancer (csPCA) alongside MRI-targeted biopsy (TB).
2

Combined biopsy (CB) significantly increased cancer detection rates for both prostate cancer (PCA) and csPCA compared to TB and SB alone.
3

Systematic biopsy contributed to the detection of csPCA by compensating for targeting errors and under-sampling in MRI-guided approaches.
4

The prevalence of csPCA was found to be 65.6% among the biopsy-naïve men included in the study.
5

Elevated prostate-specific antigen (PSA) levels and abnormal digital-rectal examinations were significant predictors for detecting PCA and csPCA.

World Journal Of Urology

by Philipp Krausewitz, Dorothea Fostitsch, Richard Weiten, Niklas Kluemper, Johannes Stein, Julian Luetkens, Glen Kristiansen, Jörg Ellinger, Manuel Ritter
December 7, 2022

1